CN119013301A - 与epcam和/或cd137结合的结合剂 - Google Patents
与epcam和/或cd137结合的结合剂 Download PDFInfo
- Publication number
- CN119013301A CN119013301A CN202380033835.4A CN202380033835A CN119013301A CN 119013301 A CN119013301 A CN 119013301A CN 202380033835 A CN202380033835 A CN 202380033835A CN 119013301 A CN119013301 A CN 119013301A
- Authority
- CN
- China
- Prior art keywords
- heavy chain
- region
- seq
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/056734 WO2023174521A1 (en) | 2022-03-15 | 2022-03-15 | Binding agents binding to epcam and cd137 |
| EPPCT/EP2022/056734 | 2022-03-15 | ||
| PCT/EP2023/056513 WO2023174952A1 (en) | 2022-03-15 | 2023-03-14 | Binding agents binding to epcam and/or cd137 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119013301A true CN119013301A (zh) | 2024-11-22 |
Family
ID=81307365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380033835.4A Pending CN119013301A (zh) | 2022-03-15 | 2023-03-14 | 与epcam和/或cd137结合的结合剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12398214B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4493591A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509555A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240157746A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119013301A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128794A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023235387A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245098A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002762A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315093A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011141A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400646A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023174521A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025056180A1 (en) * | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| WO2001007082A1 (en) | 1999-07-23 | 2001-02-01 | Glaxo Group Limited | Combination of an anti-ep-cam antibody with a chemotherapeutic agent |
| DE60035434T2 (de) * | 1999-12-27 | 2008-05-15 | Crucell Holland B.V. | Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken |
| AU2005232313A1 (en) * | 1999-12-27 | 2005-12-08 | Crucell Holland B.V. | Use of a native epitope for selecting evolved binding members from library of mutants of a protein capable of binding to said epitope |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| AU2010229705A1 (en) | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| BR112018071612A2 (pt) * | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| KR20250020679A (ko) * | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| WO2022002038A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 |
| KR20230156921A (ko) | 2021-03-12 | 2023-11-15 | 젠맵 에이/에스 | 비-활성화 항체 변이체 |
-
2022
- 2022-03-15 WO PCT/EP2022/056734 patent/WO2023174521A1/en not_active Ceased
-
2023
- 2023-03-14 JP JP2024554764A patent/JP2025509555A/ja active Pending
- 2023-03-14 CA CA3245098A patent/CA3245098A1/en active Pending
- 2023-03-14 IL IL315093A patent/IL315093A/en unknown
- 2023-03-14 EP EP23711074.7A patent/EP4493591A1/en active Pending
- 2023-03-14 WO PCT/EP2023/056513 patent/WO2023174952A1/en not_active Ceased
- 2023-03-14 CN CN202380033835.4A patent/CN119013301A/zh active Pending
- 2023-03-14 TW TW112109409A patent/TW202400646A/zh unknown
- 2023-03-14 AU AU2023235387A patent/AU2023235387A1/en active Pending
- 2023-03-14 KR KR1020247033371A patent/KR20240157746A/ko active Pending
- 2023-03-14 MX MX2024011141A patent/MX2024011141A/es unknown
- 2023-03-15 AR ARP230100638A patent/AR128794A1/es unknown
- 2023-03-15 US US18/184,120 patent/US12398214B2/en active Active
-
2024
- 2024-09-13 CL CL2024002762A patent/CL2024002762A1/es unknown
-
2025
- 2025-07-16 US US19/271,367 patent/US20260184809A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL315093A (en) | 2024-10-01 |
| TW202400646A (zh) | 2024-01-01 |
| CA3245098A1 (en) | 2023-09-21 |
| CL2024002762A1 (es) | 2025-01-24 |
| JP2025509555A (ja) | 2025-04-11 |
| AU2023235387A1 (en) | 2024-09-12 |
| US20260184809A1 (en) | 2026-07-02 |
| KR20240157746A (ko) | 2024-11-01 |
| EP4493591A1 (en) | 2025-01-22 |
| US20230295335A1 (en) | 2023-09-21 |
| AR128794A1 (es) | 2024-06-12 |
| WO2023174952A1 (en) | 2023-09-21 |
| MX2024011141A (es) | 2024-09-19 |
| WO2023174521A1 (en) | 2023-09-21 |
| US12398214B2 (en) | 2025-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020286284B2 (en) | Novel anti-CD39 antibodies | |
| JP7545438B2 (ja) | Vista抗原結合性分子 | |
| CN112020514B (zh) | 用于肿瘤特异性细胞清除的抗-cd25 | |
| CN111699200B (zh) | 针对pd-1的单域抗体和其变体 | |
| KR102907331B1 (ko) | 다중 특이적 항체 | |
| CN109843923B (zh) | 针对ctla-4的单结构域抗体及其变体 | |
| US11873346B2 (en) | VISTA antigen-binding molecules | |
| CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
| CN113811545A (zh) | 对btn2具有特异性的抗体及其用途 | |
| US12398214B2 (en) | Binding agents binding to EpCAM and CD137 | |
| WO2025056180A1 (en) | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists | |
| CA3102329C (en) | Novel anti-cd39 antibodies | |
| HK40041672B (en) | Novel anti-cd39 antibodies | |
| HK40026638A (en) | Vista antigen-binding molecules | |
| HK40026638B (en) | Vista antigen-binding molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |